WST Stock Recent News

WST LATEST HEADLINES

WST Stock News Image - zacks.com

Here, we discuss four stocks from the Dental Supplies industry that are likely to generate wealth for investors amid tariff uncertainty. These are MCK, CAH, WST and COO.

zacks.com 2025 Aug 11
WST Stock News Image - seekingalpha.com

West Pharmaceutical Services, Inc.'s Q2 results signal a return to growth, driven by strong demand for high-value products and GLP-1 agonist components. I am revamping my bullish thesis: GLP-1 drugs now provide a powerful, sustained growth catalyst beyond the company's traditional biologics and injectable therapeutics exposure. Risks include elevated valuation, potential competition, and the threat of oral GLP-1 formulations or healthcare policy changes impacting future growth.

seekingalpha.com 2025 Jul 30
WST Stock News Image - zacks.com

The consensus price target hints at a 25.3% upside potential for West Pharmaceutical (WST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

zacks.com 2025 Jul 30
WST Stock News Image - globenewswire.com

NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of West Pharmaceutical Services, Inc. (NYSE: WST) breached their fiduciary duties to shareholders.

globenewswire.com 2025 Jul 29
WST Stock News Image - zacks.com

West Pharmaceutical (WST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

zacks.com 2025 Jul 28
WST Stock News Image - zacks.com

CALX, MEDP and WST made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 28, 2025.

zacks.com 2025 Jul 28
WST Stock News Image - seekingalpha.com

My estimations suggest that the U.S. government cuts to its healthcare system will not have a significant negative impact on West Pharmaceutical's revenues. In Q2 2025, the company's revenues increased by 9.17%, suggesting that the destocking effect is vanishing. The company has low debt levels, achieving a liabilities-to-assets ratio of 25.90% in Q2 2025. Additionally, it achieved a 17.03% net profit margin in 2024.

seekingalpha.com 2025 Jul 27
WST Stock News Image - seekingalpha.com

West Pharmaceutical Services, Inc. (NYSE:WST ) Q2 2025 Earnings Conference Call July 24, 2025 8:00 AM ET Company Participants Bernard J. Birkett - Senior VP & CFO Eric M.

seekingalpha.com 2025 Jul 24
WST Stock News Image - fool.com

West Pharmaceutical Services (WST 20.87%), a global manufacturer of drug packaging and delivery systems for the pharmaceutical and healthcare industries, reported Q2 2025 earnings on July 24, 2025. The key news was a significant beat on both GAAP revenue and non-GAAP EPS.

fool.com 2025 Jul 24
WST Stock News Image - zacks.com

West Pharmaceutical's second-quarter top line continues to benefit from revenue growth in its Proprietary Products segment.

zacks.com 2025 Jul 24
10 of 50